Fallopian Tube Cancer Clinical Trials 2023

What are the top hospitals conducting fallopian tube cancer research?

Efforts to combat fallopian tube cancer, a rare and often overlooked form of gynecological cancer, are being spearheaded by top hospitals across the United States. In Houston's M D Anderson Cancer Center, researchers are currently engaged in seven active clinical trials focused specifically on this disease. With an impressive track record of 32 completed fallopian tube cancer trials since their first recorded study in 2002, this renowned institution is at the forefront of exploring innovative treatment options for patients. Similarly committed to advancing knowledge about this condition is the University of Colorado Hospital in Aurora. Their six ongoing trials and 15 previous studies conducted since initiating research in 2005 demonstrate their dedication to finding breakthroughs for fallopian tube cancer.

On the East Coast, Beebe Medical Center in Lewes has prioritized tackling this lesser-known form of cancer with five active clinical trials and a history that includes recording its first trial on fallopian tube cancer back in 2005 together with fifteen other investigations carried out afterward.Having made significant contributions to understanding and treating various diseases over its storied existence, Mayo Clinic extends its reach into Arizona's Scottsdale where they have initiated five current clinical tests while already accomplishing twelve previously executed experiments from starting pioneering investigation back until2005.Meanwhile,the Mayo Clinic branch located in Jacksonville Floridao Arizona's Scottsdale where they have initiated five current clinical tests while already accomplishing twelve previously executed experiments from starting pioneering investigation back until2005.Meanwhile,the Mayo Clinic branch located in Jacksonville Florida has also embarked onto these efforts; engaging themselves into five existing trials related towards such cases having successfully concluded ten others within sixteen years

Despite being relatively uncommon compared to other gynecological cancers like ovarian or uterine cancers,fallopian tube cancer still poses significant challenges as it often goes undiagnosed until later stages due to vague symptoms.Nonetheless,the unwavering commitment displayed by these leading medical institutions across different regions brings hope not only for those affected but also serves as inspiration pushing forward our collective fight against elusive forms of cancers worldwide

Which are the best cities for fallopian tube cancer clinical trials?

When it comes to fallopian tube cancer clinical trials, several cities emerge as prominent hubs for research and development. Denver, Colorado leads the way with 29 active trials focusing on treatments like Bevacizumab and Nivolumab, as well as Quality-of-Life Assessment. Los Angeles, California, Coloraube cancer clinical trials, several cities emerge as prominent hubs for research and development. Denver, Colorado leads the way with 29 active trials focusing on treatments like Bevacizumab and Nivolumab, as well as Quality-of-Life Assessment. Los Angeles, California follows closely behind with 24 ongoing studies investigating different treatment approaches and assessing quality of life in patients. Boston also plays a significant role in this field, hosting 18 active trials that explore options such as Gemcitabine and Cediranib Maleate. Houston, Texas and Aurora, Colorado both contribute to the advancement of knowledge through their respective 17 active trials studying various interventions. These cities offer individuals diagnosed with fallopian tube cancer access to cutting-edge clinical trials that may improve outcomes and enhance overall quality of life.

Which are the top treatments for fallopian tube cancer being explored in clinical trials?

Clinical trials are paving the way for advancements in treating fallopian tube cancer. Prominent among these trials are several top treatments that hold promise for patients:

• Pembrolizumab: Currently being explored in two active clinical trials, with a total of 24 all-time trials dedicated to fallopian tube cancer since its introduction in 2015.
• Bevacizumab: Also showing potential, this treatment is being investigated in two ongoing trials and has accumulated a substantial 47 all-time clinical trials since its listing in 2005.
• Paclitaxel: Another contender, paclitaxel is currently under investigation in two active clinical trials and boasts an impressive history of 77 all-time fallopian tube cancer studies since it was first listed back in 2002.
• Quality-of-Life Assessment: Recognizing the importance of holistic care, researchers have included quality-of-life assessments as part of their studies. This element has been incorporated into two current clinical trials and has garnered attention through its inclusion in 22 all-time fallopian tube cancer research projects starting from 2005. These diverse approaches showcase the dedication to finding effective treatments while considering patients' well-being throughout their journey towards recovery.

What are the most recent clinical trials for fallopian tube cancer?

Exciting advancements in clinical trials offer hope for those fighting fallopian tube cancer. One of the most recent trials, MORAb-202, is currently in Phase 2 and shows potential as a treatment option. Additionally, IMGN151 Open Label is being investigated in Phase 1 for its efficacy against this type of cancer. PRO1184 has entered both Phase 1 and Phase 2 studies to assess its impact on fallopian tube cancer. AB-1015 is another promising drug under investigation during its Phase 1 trial period. Lastly, olvimulogene nanivacirepvec has reached Phase 3 and holds promise as an effective treatment option for patients battling fallopian tube cancer. These ongoing trials provide renewed optimism to individuals facing this challenging disease.

What fallopian tube cancer clinical trials were recently completed?

Several recent clinical trials have made significant progress in the field of fallopian tube cancer research. Notably, a trial conducted by pharmaand GmbH concluded in March 2021, focusing on Rucaparib as a potential treatment option. Northwestern University also completed a trial investigating Irinotecan Sucrosofate during the same month. In addition, Celldex Therapeutics carried out a study exploring CDX-527, which finished in August 2020. These advancements underscore the dedication of researchers and provide hope for patients battling this form of cancer.